Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Ravulizumab for Thrombotic Microangiopathy
Recruiting2 awardsPhase 3
Atlanta, Georgia
This trial will test the safety and effectiveness of ravulizumab, an IV medication, in children with HSCT-TMA. The treatment aims to stop the immune system from damaging blood vessels. Ravulizumab is a longer-acting medication developed to reduce blood cell destruction and improve quality of life in patients with a specific blood condition.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.